Findings in the first cohort of 100 patients, after careful rediagnosis, show unipolars more vulnerable to dyskinesia, in terms of months on antipsychotics before TD, total months since first antipsychotic therapy, and grams of antipsychotic taken, than schizophrenic or schizoaffective patients. Bipolars develop dyskinesia after fewer months on antipsychotics than schizophrenics or schizoaffectives. Most patient show slow improvement in TD over years. Patients off antipsychotics do best. Lithium use is not associated with slower onset of TD, while antiparkinson drug use is. Analyses of risk factors asociated with the course of dyskinesia in the first cohort have just begun. Funds are requested to permit completion of data collection, entry and analysis for the second cohort, to see whether findings from the first cohort can be replicated, and the completion of manuscripts reporting findings. In addition, special effort will be given to examining additional risk factors based on focussed chart review for patients in both cohorts. These include early and also persistent extra-pyramidal side effects, alcoholism and substance abuse, family history of affective illness, adequacy of clinical response to antipsychotic drugs and patterns of affective symptomatology in schizophrenic and schizoaffctive patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH032675-12
Application #
2244335
Study Section
Treatment Development and Assessment Research Review Committee (TDA)
Project Start
1979-04-01
Project End
1993-06-30
Budget Start
1991-09-30
Budget End
1993-06-30
Support Year
12
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Boston Mental Health Foundation
Department
Type
DUNS #
City
Belmont
State
MA
Country
United States
Zip Code
02178
Gardos, G; Casey, D E; Cole, J O et al. (1994) Ten-year outcome of tardive dyskinesia. Am J Psychiatry 151:836-41
Yonkers, K A; Kando, J C; Cole, J O et al. (1992) Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 149:587-95
Cole, J O; Gardos, G; Boling, L A et al. (1992) Early dyskinesia--vulnerability. Psychopharmacology (Berl) 107:503-10
McElroy, S L; Dessain, E C; Pope Jr, H G et al. (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411-4
Gardos, G; Cole, J O; Haskell, D et al. (1988) The natural history of tardive dyskinesia. J Clin Psychopharmacol 8:31S-37S
Gardos, G; Perenyi, A; Cole, J O et al. (1988) Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology 1:169-72
Gardos, G; Cole, J O; Schniebolk, S et al. (1987) Comparison of severe and mild tardive dyskinesia: implications for etiology. J Clin Psychiatry 48:359-62
Gardos, G; Cole, J O; Salomon, M et al. (1987) Clinical forms of severe tardive dyskinesia. Am J Psychiatry 144:895-902